Aclaris Therapeutics, Inc. ACRS
We take great care to ensure that the data presented and summarized in this overview for Aclaris Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACRS
View all-
Bml Capital Management, LLC Zionsville, IN9.4MShares$13.1 Million7.8% of portfolio
-
Black Rock Inc. New York, NY5.2MShares$7.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.93MShares$6.85 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.28MShares$4.56 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$4.55 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA3MShares$4.17 Million0.56% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$3.83 Million0.09% of portfolio
-
Acadian Asset Management LLC Boston, MA2.14MShares$2.97 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.67MShares$2.33 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.57MShares$2.18 Million0.0% of portfolio
Latest Institutional Activity in ACRS
Top Purchases
Top Sells
About ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Transactions at ACRS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
17,716
+0.13%
|
$17,716
$1.33 P/Share
|
|
Jul 19
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
6,689
+0.05%
|
$6,689
$1.3 P/Share
|
|
Jul 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
130,317
+0.95%
|
$130,317
$1.3 P/Share
|
|
Jul 05
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
123,017
+0.91%
|
$123,017
$1.15 P/Share
|
|
Jul 03
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
143,288
+1.06%
|
$143,288
$1.16 P/Share
|
|
Jul 02
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
86,092
+0.65%
|
$86,092
$1.14 P/Share
|
|
Jul 01
2024
|
Neal Walker INTERIM PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,722
-0.21%
|
$2,722
$1.15 P/Share
|
|
Jul 01
2024
|
Neal Walker INTERIM PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,467
+0.72%
|
-
|
|
Jul 01
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
107,434
+0.81%
|
$107,434
$1.14 P/Share
|
|
Jun 28
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
1,201,000
+4.49%
|
$1,201,000
$1.13 P/Share
|
|
Jun 27
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
235,000
+1.95%
|
$235,000
$1.15 P/Share
|
|
Jun 18
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.43%
|
$50,000
$1.13 P/Share
|
|
Jun 17
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
150,000
+1.29%
|
$150,000
$1.13 P/Share
|
|
Jun 14
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
345,000
+2.95%
|
$345,000
$1.17 P/Share
|
|
Jun 13
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
528,621
+2.31%
|
$528,621
$1.15 P/Share
|
|
Jun 12
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
82,579
+0.78%
|
$82,579
$1.14 P/Share
|
|
Jun 11
2024
|
Braden Michael Leonard |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+8.78%
|
$1,000,000
$1.08 P/Share
|
|
Jun 01
2024
|
Andrew N Schiff |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+33.7%
|
-
|
|
Jun 01
2024
|
Anand Mehra |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+9.7%
|
-
|
|
Jun 01
2024
|
Maxine Gowen |
BUY
Exercise of conversion of derivative security
|
Direct |
4,660
+21.55%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 240K shares |
|---|---|
| Open market or private purchase | 4.25M shares |
| Payment of exercise price or tax liability | 62.8K shares |
|---|---|
| Open market or private sale | 12K shares |